IP Library Granted Patent US 9,840,499
Granted Patent B2
US 9,840,499 · App. 15/097,252 · Granted Dec 12, 2017

Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid

Inventors: Ali Keshavarz-Shokri (San Diego, CA); Beili Zhang (San Diego, CA); Mariusz Krawiec (Marlborough, MA)
Assignee: Vertex Pharmaceuticals Incorporated
C07D405/12A61K31/4709C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,840,499
App. No.
15/097,252
Granted
Dec 12, 2017
Kind
B2
Abstract

The present invention relates to a substantially crystalline and free solid state form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Form I), pharmaceutical compositions thereof, and methods of treatment therewith.

Claims (2)

1. A kit for the treatment of cystic fibrosis comprising a tablet for oral administration of 3-(6-(1-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid characterized as Form I; and

further comprising N-(5-hydroxy-2,4-ditertbutyl-phenyl)-4-oxo-1Hquinoline-3-carboxamide.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 10, 2017
From: KESHAVARZ-SHOKRI, ALI; ZHANG, BEILI; KRAWIEC, MARIUSZ
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 043825/0133 →
ASSIGNEE CHANGE OF ADDRESS Recorded Oct 10, 2017
From: VERTEX PHARAMACEUTICALS INCORPORATED
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 044170/0966 →
Continuity (6)
Division 14841163 · Aug 31, 2015
Division 14470836 · Aug 27, 2014
Division 13933223 · Jul 2, 2013
Division 12327902 · Dec 4, 2008
Provisional Application 61012162 · Dec 7, 2007
Related Publication 20160221995A1 · Aug 4, 2016